Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
BeiGene Ltd ADR BGNE
News
-
BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
BeiGene Says FDA Approves Tevimbra to Treat Some Esophageal Cancer Patients
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
Thinking about trading options or stock in NVIDIA, Tesla, Oracle, Broadcom, or Beigene?
BeiGene Shares Rise on First Dosing of Brukinsa
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
BeiGene to Present at Upcoming Investor Conferences
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
BeiGene Trial of Lung-Cancer Treatment Reaches Primary Endpoints
BeiGene Brukinsa Recommended for Approval From European Medicines Agency Committee
BeiGene Gets Positive CHMP Opinion for Tislelizumab to Treat Serious Esophageal Cancer
BeiGene: FDA to Review Brukinsa Combo in Relapsed, Refractory Follicular Lymphoma
BeiGene Shares Rebound After Losses From Lawsuit News